Literature DB >> 11344054

Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits.

T Mashiba1, D B Burr, C H Turner, M Sato, R L Cain, J M Hock.   

Abstract

We have previously shown that parathyroid hormone (PTH) increases cortical bone mass and mechanical strength of female rabbits after 140 days of treatment. However, cortical porosity was also shown to increase. If cortical porosity increases prior to the change in geometry, there may be a transient decrease in cortical bone strength that could make the bone more susceptible to fracture in the early phase of treatment. The purpose of this study is to examine the effects of PTH on the remodeling dynamics and mechanical properties of cortical bone in rabbits, which exhibit haversian remodeling, during the first remodeling cycle after the initiation of treatment. Fifty 9-month-old intact female New Zealand white rabbits were randomized into five groups. A baseline control group was killed at the start of the experiment. The two PTH-treated groups were given human PTH(1-34) at 10 microg/kg daily subcutaneously for 35 (P35) or 70 (P70) days. Two respective age-matched control groups (V35, V70) were injected with vehicle. Histomorphometry of the cortical bone in the tibial midshaft showed that, although intracortical activation frequency was significantly increased by PTH at 35 days, there was no significant increase of cortical porosity in the first remodeling cycle (70 days). Moreover, stimulation of cortical surface bone formation in the treated animals led to significantly greater cortical area and greater bone strength in both P35 and P70. We conclude that, although intracortical remodeling increases within the first remodeling period (70 days) in animals treated with 10 microg/kg PTH, the greater cortical area due to acceleration of bone formation on cortical surfaces increases cortical bone strength. There is no mechanical risk during the first remodeling cycle associated with intermittent PTH treatment in animals with normal bone mass.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344054     DOI: 10.1016/s8756-3282(01)00433-1

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  22 in total

1.  Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis.

Authors:  Erik R Sampson; Matthew J Hilton; Ye Tian; Di Chen; Edward M Schwarz; Robert A Mooney; Susan V Bukata; Regis J O'Keefe; Hani Awad; J Edward Puzas; Randy N Rosier; Michael J Zuscik
Journal:  Sci Transl Med       Date:  2011-09-21       Impact factor: 17.956

Review 2.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice.

Authors:  Mary L Bouxsein; Dominique D Pierroz; Vaida Glatt; Deborah S Goddard; Fanny Cavat; Renée Rizzoli; Serge L Ferrari
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

Review 4.  Denosumab: anti-RANKL antibody.

Authors:  Paul D Miller
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

5.  Parathyroid hormone PTH(1-34) increases the volume, mineral content, and mechanical properties of regenerated mineralizing tissue after distraction osteogenesis in rabbits.

Authors:  Ramune Aleksyniene; Jesper Skovhus Thomsen; Henrik Eckardt; Kristian G Bundgaard; Martin Lind; Ivan Hvid
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

6.  Bone microstructure and its associated genetic variability in 12 inbred mouse strains: microCT study and in silico genome scan.

Authors:  Ilya Sabsovich; J David Clark; Guochun Liao; Gary Peltz; Derek P Lindsey; Christopher R Jacobs; Wei Yao; Tian-Zhi Guo; Wade S Kingery
Journal:  Bone       Date:  2007-09-22       Impact factor: 4.398

7.  Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.

Authors:  Sarah K Amugongo; Wei Yao; Junjing Jia; Weiwei Dai; Yu-An E Lay; Li Jiang; Danielle Harvey; Elizabeth A Zimmermann; Eric Schaible; Neil Dave; Robert O Ritchie; Donald B Kimmel; Nancy E Lane
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

8.  The effect of calcium and vitamin D supplementation on osteoporotic rabbit bones studied by vibrational spectroscopy.

Authors:  Athina Lani; Nikolaos Kourkoumelis; Gerasimos Baliouskas; Margaret Tzaphlidou
Journal:  J Biol Phys       Date:  2014-07-09       Impact factor: 1.365

Review 9.  The use of intermittent human parathyroid hormone as a treatment for osteoporosis.

Authors:  Chad Deal
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

Review 10.  Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.

Authors:  John P Bilezikian; Mishaela R Rubin
Journal:  Curr Osteoporos Rep       Date:  2006-03       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.